The Journal of Pediatrics
Volume 145, Issue 5 , Pages 701-704, November 2004

Short-term safety assessment in the use of intravenous zoledronic acid in children

From the Institute of Endocrinology and Diabetes and Department of Orthopedics, The Children's Hospital at Westmead, Sydney, Australia; the Department of Pediatrics and Adolescent Medicine, University of Innsbruck, Austria; and the Department of Pediatrics, KK Women's and Children's Hospital, Singapore.

Received 2 December 2003; received in revised form 27 April 2004; accepted 28 June 2004.

The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.

HCM, Malignancy-induced hypercalcemia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors have no potential, perceived, or real conflict of interest.

PII: S0022-3476(04)00632-8

doi:10.1016/j.jpeds.2004.06.066

The Journal of Pediatrics
Volume 145, Issue 5 , Pages 701-704, November 2004

Article Tools

* Image Usage & Resolution